Dylann Cohn-Emery

Patients with renal cell carcinoma experienced a better overall survival when treated with nivolumab plus cabozantinib regardless of whether or not they underwent a nephrectomy previously.

Francesco Passamonti, MD, discusses the future of treatment for patients with polycythemia vera such as adaptive therapies and the utilization of novel targets.

Pralsetinib was well tolerated, while demonstrating robust and durable anti-tumor activity when treating heavily pretreated patients with multiple RET fusion–positive advanced solid tumors.

A phase 1 trial of the investigational agent CLN-081 indicates antitumor activity coupled with a tolerable safety profile as treatment of patients with non–small cell lung cancer and EGFR exon 20 insertion mutations.

Five-year follow-up data from the SOLO-1 trial continue to show progression-free survival benefit of olaparib as maintenance therapy following platinum-based chemotherapy in the frontline setting for ovarian cancer.

Patients with newly diagnosed ovarian cancer who had interval debulking surgery and visible residual disease showed promising outcomes when treated with the PARP inhibitor niraparib, according to a post hoc analysis of a phase 3 clinical trial.

Patients with advanced lung cancer whose tumors harbor an NTRK gene fusion with or without central nervous system metastases were found to have high response rates, durable responses, and extended survival benefit with larotrectinib.

As third- or fourth-line therapy for patients with metastatic RCC, tivozanib hydrochloride demonstrated a statistically significant increased quality-adjusted time without symptoms of disease and toxicity compared with sorafenib.

Lenvatinib monotherapy was an effective first-line therapy for patients with unresectable hepatocellular carcinoma, according to data from a retrospective, real-world analysis.

The study found that favorable outcomes after treatment with lapatinib (Tykerb) were demonstrated by early declines in circulating tumor cell counts (CTCs) in patients with metastatic breast cancer who initially had HER2-negative primary tumors but positive HER2 CTCs.

The ongoing phase 1/2 DREAMM-6 trial found that the addition of belantamab mafodotin to bortezomib and dexamethasone elicited high response rates and a suitable safety profile in patients with relapsed or refractory multiple myeloma.

A phase 1 trial found that MEDI-570 demonstrated clinical activity with durable responses, as well as acceptable safety and tolerability in patients with relapsed or refractory angioimmunoblastic T-cell lymphoma and peripheral T-cell lymphoma.

CC-92480 in combination with dexamethasone demonstrated favorable activity and safety data in patients with heavily pretreated relapsed or refractory multiple myeloma.